---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-23-024218"
form_type: "8-K"
ticker: "CYCN"
cik: "0001755237"
company_name: "Cyclerion Therapeutics, Inc."
filed_at: "2023-05-12T23:59:59+00:00"
generated_at: "2026-06-15T02:40:09.011405+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Cyclerion sells zagociguat & CY3018 for $8M cash + 10% equity; CEO to lead NewCo

## Summary
- Receives $8M cash at closing and 10% equity in NewCo with anti-dilution protection through $100M post-money.
- NewCo investors (Invus, Venrock, J Wood Capital, Sanofi Ventures) commit $81M to develop zagociguat and CY3018.
- CEO Peter Hecht will transition to NewCo as CEO; Errol De Souza elected Chair of Cyclerion Board.
- Signing triggers $5M equity investment by Hecht at $0.434/share; proceeds plus $8M expected to fund operations for 12+ mos.
- Q1 2023 cash $7.2M (down from $13.4M year-end 2022); company to seek later-stage CNS assets under new leadership.

## SEC filing metadata
- accession: 0001140361-23-024218
- form_type: 8-K
- ticker: CYCN
- cik: 0001755237
- company_name: Cyclerion Therapeutics, Inc.
- filed_at: 2023-05-12T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 1.01, 2.02, 7.01, 3.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1755237/000114036123024218/0001140361-23-024218-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1755237/000114036123024218/brhc20052804_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-23-024218
- JSON: https://secwatch.observer/filing/0001140361-23-024218.json
- Plain text: https://secwatch.observer/filing/0001140361-23-024218.txt

## Key facts
- Earnings Releases
  Cyclerion Therapeutics, Inc. reported financial results for first quarter 2023.
  - Period: first quarter 2023
  - Result: reported results
  source text: Cyclerion Therapeutics, Inc. (Nasdaq: CYCN) today announced corporate updates and first quarter 2023 financial results.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1755237/000114036123024218/0001140361-23-024218-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.